Wordt geladen...
Frequent Klebsiella pneumoniae Urinary Tract Infections in a Patient Treated with Ruxolitinib
Ruxolitinib is a targeted agent that inhibits Janus 2 Kinase and is approved for use in Polycythemia Vera and Primary Myelofibrosis. Its mechanism of action involves inhibition of cellular proliferation via the Janus kinase/signal transducer and activator of transcription proteins pathway. Ruxolitin...
Bewaard in:
| Gepubliceerd in: | Antibiotics (Basel) |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6784127/ https://ncbi.nlm.nih.gov/pubmed/31527456 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antibiotics8030150 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|